THE RESULTS OF A STUDY OF CHEMOTHERAPY WITH BEVACIZUMAB, OXALIPLATIN AND PACLITAXEL IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER
https://doi.org/10.18027/2224-5057-2017-7-4-42-47
Abstract
Breast cancer (BC) is the most frequently diagnosed cancer among women. Triple negative breast cancer (TNBC) is a special subtype of BC, representing 15% of all breast cancers, is characterized by the absence of receptors to estrogen, progesterone and expression of HER-2 growth factor. This subtype carries an aggressive course, more frequently affects younger patients, a poor prognosis and a high risk of early recurrence with development of metastases. The heterogeneity of the disease and the absence of well-known molecular targets (hormone receptors and amplification of HER-2/neu) explains the complicity in choosing the optimal therapeutics regimens. Less than 30% of women with metastatic TNBC survive 5 years. There is a major need to develop new effective treatment options for patients with this aggressive subtype of breast cancer, that would lead to improve patient outcome.
About the Author
O. V. Smirnova
Clinical Oncology Dispensary No. 1 of the Moscow Healthcare Department; A. I. Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Olga V. Smirnova - MD, PhD student COD No. 1; Department of Oncology and Radiology, A.I. Yevdokimov MSUMD
Russian Federation
Olga V. Smirnova - MD, PhD student COD No. 1; Department of Oncology and Radiology, A.I. Yevdokimov MSUMD
References
1. Чиссов В.И., Дарьялова С.Л. Онкология. М.: ГЭОТАР-Медиа, 2009, С. 38–43. [Chissov V. I., Dar’yalova S. L. Onkologiya, Moscow: GEOTAR-Media, 2009, pp. 38–43 (In Russ.)].
2. American Cancer Society, Cancer Facts & Figures, Atlanta: American Cancer Society, 2016.
3. Prat A., Perou C.M. et al. Molecular stratification of triple negative breast cancer, Mol. Oncol., 2010.
4. rvin W. J. Jr, Carey L.A. What is triple-negative breast cancer? Eur. J. Cancer., 2008, Vol. 44 (18), pp. 2799–2805.
5. Dent R., Trudeau M., Pritchard A. L., Eklund A.C. et al. Triple-negative breast cancer: clinical features and patterns of recurrence, Clin. Cancer Res., 2007, Vol. 13, pp. 4429–4434.
6. O’Shaughnessy J., Schwartzberg L., Danso M.A. et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer, J. Clin. Oncol., 2014, Vol. 32, pp. 3840–3847.
7. Twelves C., Cortes J., Vahdat L. et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res. Treat., 2014, Vol. 148, pp. 553–561.
8. Lehmann B.D., Bauer J.A., Chen X. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J. Clin. Invest., 2011, Vol. 121, pp. 2750–2767.
9. Гарин А.М., Базин И.С. Справочник по лекарственной терапии солидных опухолей. М.: ИНФОТЕХ; ЛЕКСРУС, 2015. С. 50–100. [Garin A.M., Bazin I.S. Spravochnik po lekarstvennoy terapii solidnykh opukholey, Moscow: INFOTEKH; LEKSRUS, 2015, pp. 50–100 (In Russ.)].
10. ICH Guidelines, Good Clin. Pract. J., 1998, Vol. 5, No. 4, pp. 27–37.
Review
For citations:
Smirnova O.V. THE RESULTS OF A STUDY OF CHEMOTHERAPY WITH BEVACIZUMAB, OXALIPLATIN AND PACLITAXEL IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER. Malignant tumours. 2017;7(4):42-47. (In Russ.) https://doi.org/10.18027/2224-5057-2017-7-4-42-47
Views:
1194
Email this article 